Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MenACWY-CRM + MMRV
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular, Subcutaneous
01
Overview
MenACWY-CRM + MMRV refers to the co-administration of a quadrivalent meningococcal conjugate vaccine (MenACWY-CRM, brand name Menveo) with the measles, mumps, rubella, and varicella vaccine (MMRV). MenACWY-CRM is a conjugate vaccine in which the capsular polysaccharides from Neisseria meningitidis serogroups A, C, W, and Y are conjugated to the diphtheria toxin mutant CRM197. It provides protection against meningococcal serogroups A, C, W, and Y, but not against serogroup B. MMRV provides protection against measles, mumps, rubella, and varicella. Clinical studies have shown that simultaneous administration of these vaccines at 12 months of age is well-tolerated and immunogenic without significant safety concerns.
- Brand names
- Menveo + ProQuad
- Other names
- MMRV-Novartis Vaccines-meningococcal infection-measles-mumps-rubella-varicellaMenACWY-CRM + MMRVMenveo + MMRV
02
Targets
MenA-BCR (B-cell receptor specific for Neisseria meningitidis serogroup A capsular polysaccharide)BCR (Immunoglobulin G B Cell Receptor)B-cell receptor (BCR) specific for Neisseria meningitidis serogroup W-135 capsular polysaccharideBCR-MenY-CPS (B-cell receptor specific for Neisseria meningitidis serogroup Y capsular polysaccharide)B-cell receptor specific for measles virus hemagglutinin and fusion proteinBCR-MuV-HN/F (B-cell receptor specific for mumps virus hemagglutinin-neuraminidase and fusion protein)BCR-RuV-E1/E2 (B-cell receptor (BCR) specific for rubella virus E1 and E2 envelope protein epitopes)Varicella-zoster virus glycoprotein-specific B-cell receptorHuman leukocyte antigen class I and II molecules presenting measles, mumps, rubella, and varicella-zoster virus peptidesHLA-II/CRM197 (HLA class II molecules presenting CRM197-derived peptides)TCR-CRM197 (CRM197-specific T-cell receptor)VZV (Varicella-zoster virus)Group Y CPS (Neisseria meningitidis group Y capsular polysaccharide)
Beyond the preview
Go deeper on MenACWY-CRM + MMRV.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MenACWY-CRM + MMRV.